Open Journal Systems

Models for accessing biomedical innovation in Asia

Young-Hwa Kim, Ajay Gautam

Abstract

Asian countries are striving to transition into innovation-driven economies, and healthcare is a key sector on government agendas. Strong funding at academic institutions, high-impact publications, state-of-the-art clinical infra-structures, vast talent pools, increasing start-up activities and strengthening intellectual property regimes, all aligned with coherent government policies, is creating an evolving innovation ecosystem in countries such as China, South Ko-rea, Singapore, Taiwan and India. Such factors have fuelled a desire from global pharmaceutical companies to seek in-novation in Asia. In this article, we review the varied strategies of large multinationals using two key aspects—the capital investments and operational model—to understand such diverse approaches. Based on a qualitative and quantita-tive analysis, we have classified these strategies into four distinct approaches—“Captive”, “Partner”, “Service” and “Open” models—and discussed case studies that fit into each of these clusters. The model may provide global pharma-ceutical companies with a framework to evaluate their respective approaches for sourcing innovation and align them with the operational, financial, business and strategic needs of their organizations in Asia.


Keywords

biomedical innovation; capital investments; operating models; Asia; in-licensing; joint ventures; research collaborations; open innovation

Full Text:

PDF

References

Chakma J, Sun G H, Steinberg J D, et al. 2014, Asia’s ascent—global trends in biomedical R&D expenditures. New England Journal of Medicine, vol.370(1): 3–6.

http://dx.doi.org/10.1056/NEJMp1311068.

Moses H III, Matheson D H M, Cairns-Smith S, et al. 2015, The anatomy of medical research: US and international comparisons. Journal of the American Medical Association, vol.313(2): 174–189.

http://dx.doi.org/10.1001/jama.2014.15939.

Chakma J, Sammut S M and Agrawal A, 2013, Life sciences venture capital in emerging markets. Nature Biotechnology, vol.31(3): 195–201.

http://dx.doi.org/10.1038/nbt.2529.

Gautam A and Yang S, 2014, Market watch: a framework for biomedical innovation in emerging markets. Nature Reviews Drug Discovery, vol.13(9): 646–647.

http://dx.doi.org/10.1038/nrd4413.

Gautam A, 2015, Market watch: Evolution of Chinese bioclusters as a framework for investment policies in emerging markets. Nature Reviews Drug Discovery, vol.14(1): 8.

http://dx.doi.org/10.1038/nrd4516.

Xia C and Gautam A, 2015, Biopharma CRO industry in China: landscape and opportunities. Drug Discovery Today.

http://dx.doi.org/10.1016/j.drudis.2015.02.007.

Ma Q and Lu A Y H, 2011, Pharmacogenetics, phar-macogenomics, and individualized medicine. Pharma-cological Reviews, vol.63(2): 437–459.

http://dx.doi.org/10.1124/pr.110.003533.

Mitsudomi T, 2014, Molecular epidemiology of lung cancer and geographic variations with special reference to EGFR mutations. Translational Lung Cancer Research, vol.3(4): 205–211.

http://dx.doi.org/10.3978/j.issn.2218-6751.2014.08.04.

2010, Evolving R&D for emerging markets. Nature Reviews Drug Discovery, vol.9(6): 417–420. http://dx.doi.org/10.1038/nrd3204.

Lilly’s Commitment to global innovation reinforced with opening of new diabetes-focused research and develop-ment center in Shanghai n.d., viewed April 6, 2012,

Lilly and innovent biologics announce a strategic alli-ance to bring oncology therapies to patients in China and around the world n.d., viewed April 6, 2015,

Hanmi enters into a co-development/marketing agree-ment with GSK n.d., viewed April 15, 2015,

Sanofi-aventis and glenmark pharmaceuticals sign license agreement on novel agents to treat chronic pain n.d., viewed April 7, 2015,

Lilly and Glenmark Pharmaceuticals announce license agreement n.d., viewed April 7, 2015,

Pfizer and Hisun announce launch of Hisun-Pfizer Pharmaceuticals Co., Ltd. n.d., viewed April 10, 2015,

Lilly open innovation portal n.d., viewed April 10, 2015,

AstraZeneca open innovation portal n.d., viewed April 10, 2015,

Robertson M N, Ylioja P M, Williamson A E, et al. 2014, Open source drug discovery – a limited tutorial. Parasitology, vol.141(1): 148–157.

http://dx.doi.org/10.1017/S0031182013001121.

Khanna I, 2012, Drug discovery in pharmaceutical industry: productivity challenges and trends. Drug Discovery Today, vol.17(19–20): 1088–1102.

http://dx.doi.org/10.1016/j.drudis.2012.05.007.

Paul S M, Mytelka D S, Dunwiddie C T, et al. 2010, How to improve R&D productivity: the pharmaceutical indu-stry’s grand challenge. Nature Review Drug Discovery,

vol.9(3): 203–214.

http://dx.doi.org/10.1038/nrd3078.

Merck hands over China joint venture to partner Simcere Pharma n.d., viewed April 10, 2015,

Lilly to close Singapore Discovery Center n.d., viewed April 10, 2015,

Pfizer to lop off Asian research unit and amid major R&D downsizing n.d., viewed April 10, 2015,

Lilly asia ventures n.d., viewed April 10, 2015,

Novartis venture fund n.d., viewed April 10, 2015,


DOI: http://dx.doi.org/10.18063/jmds.v1i1.108
(356 Abstract Views, 338 PDF Downloads)

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 Young-Hwa Kim, Ajay Gautam

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.